Absci Corporation (ABSI)

NASDAQ: ABSI · IEX Real-Time Price · USD
-0.05 (-3.47%)
At close: Nov 27, 2023, 4:00 PM
+0.03 (2.09%)
After-hours: Nov 27, 2023, 5:32 PM EST

Company Description

Absci Corporation operates as a generative AI drug creation company in the United States.

Its integrated drug creation platform identifies novel drug targets and creates biotherapeutic candidates.

The company was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation
Absci logo
Country United States
Founded 2011
IPO Date Jul 22, 2021
Industry Biotechnology
Sector Healthcare
Employees 193
CEO Sean McClain

Contact Details

18105 Se Mill Plain Blvd
Vancouver, Washington 98683
United States
Phone (360) 949-1041
Website absci.com

Stock Details

Ticker Symbol ABSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001672688
CUSIP Number 00091E109
ISIN Number US00091E1091
Employer ID 85-3383487
SIC Code 8731

Key Executives

Name Position
Sean McClain Founder, Chief Executive Officer, President and Director
Dr. Sarah Korman J.D., Ph.D. Chief Legal Officer and Corporate Secretary
Gregory T. Schiffman CPA, CPA, MBA Chief Financial Officer
Todd Bedrick CPA Senior Vice President and Chief Accounting Officer
Jack Gold Chief Marketing Officer
Melissa Patterson Ph.D. Chief of Staff
Denise Dettore Chief People Officer
Dr. Andreas Busch Ph.D. Chief Innovation Officer
Jonathan Eads M.S. Senior Vice President of Informatics
Thomas Wrona J.D., Ph.D. Senior Vice President of Intellectual Property

Latest SEC Filings

Date Type Title
Nov 14, 2023 10-Q Quarterly Report
Nov 14, 2023 8-K Current Report
Sep 5, 2023 8-K Current Report
Aug 17, 2023 8-K Current Report
Aug 14, 2023 8-K Current Report
Aug 14, 2023 10-Q Quarterly Report
Jun 16, 2023 424B5 Filing
Jun 16, 2023 8-K Current Report
Jun 6, 2023 8-K Current Report
May 30, 2023 10-K/A [Amend] Annual report